Company intelligence / Profile preview

TRF Pharma

Burlingame, California, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

TRF Pharma developed therapies for diseases involving aberrant cell adhesion to blood vessel walls, focusing on sickle cell disease and cancer metastasis. Its main clinical candidate was pentosan polysulfate sodium (TRF-1101), which reached Phase 2 trials in sickle cell disease but was ultimately discontinued. The company is now out of business.

Therapeutic areas: HematologyOncology
Modalities: Small molecule (heparin derivatives and heparinoid drugs)Polysulfated polysaccharide (pentosan polysulfate sodium)
Industry: Biotech

Beyond the preview

Go deeper on TRF Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TRF Pharma.

Explore the full profile